1-2 of 2
Olivia Spleiss
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, Annika Dufour, Jianguo Zhi, Tadeusz Robak, Sergey I. Moiseev, Anna Dmoszynska, Philippe Solal-Celigny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V. Afanasiev, Loree Larratt, Viktor A. Rossiev, Isabelle Bence-Bruckler, Christian H. Geisler, Marco Montillo, Michael K. Wenger, Martin Weisser
Journal: Blood
Blood (2010) 116 (20): 4212–4222.
https://doi.org/10.1182/blood-2010-03-272765
Published: 2010
Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD
Journal: Blood
Blood (2009) 114 (22): 2338.
https://doi.org/10.1182/blood.V114.22.2338.2338
Published: 2009